Please refer attachment
Awaiting price reaction for this filing.
Piramal Pharma's board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. On a standalone basis, FY25 revenue from operations grew 20.4% YoY to Rs. 5,285.71 crores, while profit after tax jumped ~76.8% to Rs. 691.40 crores. Consolidated FY25 revenue rose ~12% to Rs. 9,151.18 crores and PAT surged to Rs. 91.13 crores from Rs. 17.82 crores, supported by the absence of exceptional charges seen in FY24. The board recommended a final dividend of Rs. 0.14 per share (face value Rs. 10), subject to shareholder approval. Mr. Neeraj Bharadwaj (Carlyle nominee) resigned and was replaced by Mr. Amit Jain as Carlyle's representative on the board. Mr. Jairaj Purandare was re-appointed as Independent Director for a second five-year term from February 9, 2026.
Strong FY25 performance with double-digit revenue growth and sharp profit expansion on both standalone and consolidated bases is a positive signal for shareholders. The small dividend (Rs. 0.14 per share, ~1.4% yield) suggests focus on reinvestment rather than payouts. Carlyle's board seat change is a routine nominee swap with no operational impact.